CALL - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Börse Stuttgart 11:41:36 07/05/2024 am IST | ||
| 20.29 EUR | +0.45% |
|
| Current month | -3.56% | ||
| 1 month | +0.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/24/07 | 20.29 | +0.45% | 0 |
| 06/24/06 | 20.2 | 0.00% | 0 |
| 03/24/03 | 20.2 | -6.78% | 0 |
| 02/24/02 | 21.67 | +2.99% | 0 |
| 30/24/30 | 21.04 | -0.47% | 0 |
Delayed Quote Börse Stuttgart
Last update May 07, 2024 at 11:41 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VN5PGC |
| ISIN | DE000VN5PGC7 |
| Date issued | 21/11/2016 |
| Strike | 97.55 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.07 € |
|---|---|
| Lowest since issue | 0.23 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
882.6
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.95%
- Stock Market
- Certificates
- Certificat